Upadacitinib Sustains Repigmentation at Week 76 in Non-Segmental Vitiligo
Long-term extension data show repigmentation maintained through 76 weeks in non-segmental vitiligo patients receiving oral upadacitinib, positioning the oral JAK1 inhibitor as a durability signal rat…